Readline, a Shenzhen-based bio-pharmaceutical firm, has secured 300 million yuan ($43 million) in a Series B round led by CoStone Capital, the firm announced via its WeChat channel on Friday.
Continue reading with Data Vantage
Venture-backed company data in SE Asia, India, Pakistan, Bangladesh.
Instant investment updates and valuations.
Tailored search, 3 monthly reports.
Industry-trusted platform.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
